Last Update

2016-05-17T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Richard Chipkin?

Dr. Richard E. Chipkin

President and Chief Executive Officer

Psyadon Pharmaceuticals , Inc.

HQ Phone: (301) 919-2020

Email: r***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Psyadon Pharmaceuticals , Inc.

20451 Seneca Meadows Parkway

Germantown, Maryland 20876

United States

Company Description

Psyadon Pharmaceuticals, Inc. is a company that develops drugs for the treatment of diseases afflicting the central nervous system. Founded in 2008, the firm is based in Germantown, Maryland. It receives financial support from New Enterprise Associates (C ... more

Background Information

Affiliations

Board Member
Tech Council of Maryland

Board Member
Technology Vision Group LLC

Education

Ph.D.

Pharmacology

Medical College of Virginia

undergraduate degree

Pharmacology

State University of New York at Albany

Web References (121 Total References)


Board of Directors | Tech Council of Maryland

www.techcouncilmd.com [cached]

Richard E. Chipkin, Ph.D. President and Chief Executive Officer Psyadon Pharmaceuticals


Psyadon Pharmaceuticals Home Page

www.psyadonrx.com [cached]

Dr. Richard E. Chipkin, PhD, President and CEO

Dr. Chipkin has more than 20 years experience at both biotech and big pharmaceutical companies. Most recently, he was President and CEO of Psychiatric Genomics. While there, he raised two rounds of venture capital financing, re-organized the company, and negotiated multiple academic licenses. Prior to that, he worked at Schering-Plough Corporation in the Global Business Development Group, where he was responsible for licensing and acquisition in multiple therapeutic areas. In this capacity, Dr. Chipkin negotiated several multi-million dollar research & development and development/marketing deals, including the license for INTEGRILIN®, currently a $250M/year product. Earlier in his career at Schering-Plough, he held positions in both preclinical and clinical neuropharmacology research. Among his accomplishments in the research arena were the discovery of novel analgesic and antipsychotic drugs, including the identification and human testing of ecopipam -- the world's first selective D1 antagonist. Dr. Chipkin received his undergraduate degree from the State University of New York at Albany and his PhD in Pharmacology from the Medical College of Virginia. He did post-doctoral work at the University of Colorado Medical Center.


Richard Chipkin, President ...

www.orphan-drugs.org [cached]

Richard Chipkin, President and CEO of Psyadon, stated, "We are honored to be selected as the first company the TSA has collaborated with on a clinical drug study.


Tourette Syndrome Research | Greater Missouri TSA

missouritsa.org [cached]

Richard Chipkin, President and CEO of Psyadon, said: "We are honored to be selected as the first company the TSA has collaborated with on a clinical drug study.


Paragon Bioservices CEO Elected to the MdBio Division Board of Directors

www.paragonbioservices.com [cached]

• Richard E. Chipkin, Ph.D., President and CEO, Psyadon Pharmaceuticals

Similar Profiles

Other People with this Name

Other people with the name Chipkin

Joel Chipkin
Directors of the Milton and Betty Katz Jewish Community Center of Atlantic City

Stephen Chipkin
Jewish Communal Appeal

Jessica Chipkin
Geneca LLC

Roy Chipkin
CB Richard Ellis Inc

Paul Chipkin
Staten Island Peer Advocacy

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory